Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
R-3750 in Late-Stage Acute Respiratory Distress Syndrome
NCT07646028Phase 1Not yet recruiting
- Sponsor
- Rise Therapeutics
- Start
- Sep 2026
- Primary completion
- Oct 2028
01
Overview
Phase 1, open-label trial of R-3750 in acute respiratory distress syndrome (ARDS) (2 cohorts), sponsored by Rise Therapeutics. Primary endpoint: Safety and Tolerability of R-3750 at 90 days. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
R-3750
03
Conditions
acute respiratory distress syndrome (ARDS)
Beyond the preview
Go deeper on NCT07646028.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07646028.